CROs offering EU EMA Regulatory Strategy with Radiopharmaceutical
EU EMA Regulatory Strategy combined with Radiopharmaceutical is a common shortlist filter for sponsors evaluating CRO partners. This explore page lists organizations that publicly map to both dimensions, so you can move from taxonomy browsing to a tighter candidate set without rebuilding filters from scratch.
Profiles here are fit-first: open each listing for scope, geography, regulatory posture, and provenance-backed facts. The directory does not rank these rows as a single "best" answer — use them to assemble a right-sized outreach list for your program stage and quality bar.
When you need adjacent criteria (indications, claim status, or cross-category search), continue to the main search experience and layer filters on top of this service × modality starting point.
Auto-generated by BioBM Editorial AI.
Matching companies
- Labcorp
Labcorp Early Development Services is part of Labcorp, a global life sciences and healthcare company offering integrated drug development and diagnostic services. The organization supports nonclinical research, central laboratory services, early phase development, regulatory…
- Medpace
Full-service CRO with 30+ years of organic growth, offering integrated clinical development services across all phases with wholly-owned central labs, bioanalytical lab, imaging core lab, and Phase I unit.
- Novotech
Global full-service CRO specializing in early-phase and oncology trials across 50+ countries, with expertise in cardiovascular, cell and gene therapy, and radiopharmaceutical development.
- Pharmaron
Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Related: EU EMA Regulatory Strategy service page · Radiopharmaceutical modality page
Markdown mirror: /explore/svc_regulatory_eu_ema/mod_radiopharma.md